Clinical Trial Update: 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating 24-week efficacy and safety of empagliflozin in Black/African American patients with Type 2 diabetes mellitus and hypertension; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2, Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2018-07-31